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Abstract
AIM: To examine the sensitivity and accuracy of real-time
polymerase chain reaction (PCR) for the quantification of
hepatitis B virus (HBV) DNA in semen.
METHODS: Hepatitis B viral DNA was isolated from HBV
carriers’ semen and sera using phenol extraction method
and QIAamp DNA blood mini kit (Qiagen, Germany). HBV
DNA was detected by conventional PCR and quantified by
TaqMan technology-based real-time PCR (quantitative
polymerase chain reaction (qPCR)). The detection threshold
was 200 copies of HBV DNA for conventional PCR and 10
copies of HBV DNA for real time PCR per reaction.
RESULTS: Both methods of phenol extraction and QIAamp
DNA blood mini kit were suitable for isolating HBV DNA
from semen. The value of the detection thresholds was
500 copies of HBV DNA per mL in the semen. The viral
loads were 7.5×107 and 1.67×107 copies of HBV DNA per
mL in two HBV infected patients’ sera, while 2.14×105
and 3.02×105 copies of HBV DNA per mL in the semen.
CONCLUSION: Real-time PCR is a more sensitive and
accurate method to detect and quantify HBV DNA in the
semen.
© 2005 The WJG Press and Elsevier Inc. All rights reserved.
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INTRODUCTION
Human hepatitis B virus (HBV) is the major epidemiological
agent of acute and chronic hepatitis, cirrhosis, and
hepatocellular carcinoma[1-3]. At present, around 10-15%
of individuals (estimated 200 million people) are chronically
infected with HBV in China, and HBV-associated
hepatocellular carcinoma (HCC) has become the country’s
second most lethal disease.
One of the major HBV transmission pathways is
parenteral[4,5]. HBV is therefore in most cases transmitted
to individuals at birth or in the postnatal period by infected
mothers, less commonly through close contact with infected
fathers, siblings, and relatives during early childhood[2]. In
developed countries, sexual transmission plays a major
role in infecting individuals[3]. Mother-to-baby vertical
transmission gives a large number of HBV carriers in China
and other eastern Asian countries. It has also been reported
that fetuses become infected in the uterus by their fathers
as a result of transmission through sexual contact, although
the mothers are negative for any HBV marker[6]. Therefore,
the viral load in the semen or vaginal secretions is a very
important parameter for safe sex and human reproduction.
Few attempts have been made to monitor HBV viral
load in semen or vaginal secretions. Many people, especially
in conservative Asian cultures, are reluctant to disclose
information on their sexual habits, and unwilling to
provide semen or vaginal secretions for epidemiological
studies. When semen or vaginal secretions become available
for study, they are in far smaller volumes than typical
blood samples, and their viral titers are much lower than
those of blood samples. These factors have hindered the
progress of virological studies of reproduction-related body
fluids. Although several methods have been developed for
the detection of HBV DNA in semen[7-10], and HBV is
routinely monitored when semen is screened for artificial
insemination[11-13], the quantitative data produced have
been disappointingly small. Southern blot has been used to
estimate HBV viral load in semen in a study conducted 15
years ago[7], but no follow-up was made, probably because
the work involved would have been tedious, time-consuming,
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and possibly of limited accuracy. At present, there are still
insufficient virological data to enable the risk factors for
HBV infection through semen to be evaluated.
The sensitive quantitative real-time PCR (qPCR) provides
an opportunity to investigate the viral load in the semen of
HBV patients or carriers seeking assisted reproduction.
The qPCR technology has greatly improved the precision
of DNA quantification[14-16]. In this paper, we compared
two different methods for the preparation of HBV DNA
from HBV carriers’ semen, and presented a TaqMan
technology-based assay to quantify HBV DNA in semen.
Our assay is highly sensitive, and theoretically suitable for
quantifying most HBV genotypes.
MATERIALS AND METHODS
Sera and semen samples
The study was conducted in patients who were seeking
assisted reproduction in Luofu Hospital, Shenzhen, in
2003 and 2004. In accordance with the standard protocols,
all patients who received assisted reproduction were
systematically screened for serum hepatitis B virus surface
antigen (HBsAg), hepatitis B surface antibody (HBsAb),
hepatitis B e antigen (HBeAg), and hepatitis B e antibody
(HBeAb) with commercially-available enzyme immunoassays
(Abbott Laboratories, Chicago, IL, USA). The recommended
viral markers including human immunodeficiency virus
antibody (HIV Ab), and hepatitis C antibody (anti-HCV)
were also detected. Hepatitis B core antibody (HBcAb)
was also systematically tested by RIA (Corab; Abbott).
Semen HBV DNA was detected by PCR. All patients were
tested with liver function tests (including serum alanine
aminotransferase, serum albumin and bilirubin) before
assisted reproductions were carried out. Five patients were
selected for this study. Two patients were positive for
HBsAg, HBeAg and anti-HBc, and their serum ALT levels
were normal over 6 mo. Two patients presented HBsAb
only. One patient with all HBV markers negative (s, e, and
c antibody negative; s and e antigene negative) was selected
as a control (Table 1). HCV or HIV was not detected by
RT-PCR in these patients’ sera. Patients were asked not to
ejaculate for five days before semen samples were collected.
Informed consent was obtained from all patients. Study
procedures were approved by the Ethics Committee of
Luofu Hospital and the Chinese University of Hong Kong.
Each ejaculation was liquefied for at least 30 min at 37 .
The sperm concentration and percentage of  motile
spermatozoa were evaluated by Makler chamber, under a
phase-contrast microscope. The serum and semen samples
were stored at -20  until use.
Isolation of viral DNA
The spermatozoa in the semen were removed by centrifugation
at 3 000 g at 4  for 10 min. Different amounts of each
seminal plasma (10, 50, and 200 µL) were used to isolate
viral DNA by two methods. Viral DNA was isolated with
QIAamp Blood Mini Kit (Qiagen, Germany) following
manufacturer’s instructions. In the case of a small amount
of semen, up to 200 µL of PBS was supplemented to avoid
loss of viral DNA. In the phenol extraction experiments,
an equal volume of saturated phenol (Sigma, St. Louis, USA)
was added to the samples, and vortexed for 1 min. After
centrifugation at 13 000 g for 10 min, upper layer was
transferred to a fresh tube and repeated the extraction with
phenol-chloroform (1:1). Then 0.1 volume of  3 mol/L
potassium acetate (pH 5.2), 1 µL glycogen (1 µg/µL,
invitrogen), and 2.5 volume of absolute alcohol were added
to the extract, and frozen at -80  for 20 min. The viral
DNA was then precipitated by centrifugation at 13 000 g
for 10 min, and finally resuspended in 20 µL TE buffer. As
a control, 200 µL of each serum sample was used to isolate
HBV DNA.
Standard HBV DNA
A plasmid containing Chinese HBV genome (pHBV-adr),
kindly donated by Professor Yuan Wang[17], was isolated by
CsCl purification. The DNA concentration was measured
by A260 and verified by agarose gel electrophoresis. The
copy number was determined by its molecule weight.
Oligonucleotide design
Previously, we used commercial detection kits to quantify
HBV DNA in the sera[17]. To develop cheaper reagents and
cover more HBV genotypes, we designed a set of primers
and probes for this study. Various HBV genotypes undergo
rapid mutagenesis because their reverse-transcriptase (RT)
lacks proof-reading functions. To obtain specific PCR
primers, we aligned over 150 sequences representing all
the HBV genotypes, and designed a pair of primers for
amplification of the S gene (conventional PCR) and core
gene (quantitative PCR). Sequence alignments were carried
out with the default settings using the BLAST algorithm
(www.ncbi.nlm.nih.gov). Primers were chosen to facilitate
amplification of  most HBV genotypes. To achieve this goal,
degenerated primers were designed. The primer pairs
5’-AGACTCGTGGTGGACTTCTCTC-3’ (forward) and
5’-AAGCCA(A/T/C/G)ACA(A/G)TGGGGGAAAGC-3’
(reverse) were used for amplification of the S gene in
conventional PCR experiments while primers 5’-
CCTGGGTGGGAAGTAATTTGG-3’ (forward), 5’-
TTTTA(A/G)GCCCATATTAACATTGACAT-3 ’
(reverse),  and TaqMan probe 5’-FAM-AGACCCA-
GCATCCAGGGAATTAGTAGTCAGC-TAMRA-3’ were
used to amplify core gene fragments in real-time PCR
experiments. These primers could target different regions,
thereby providing an important cross-check for the results.
Conventional PCR
Conventional PCR was used to detect HBV DNA in sera
Table 1  HBV status in sera of HBV carriers
       Antigen-antibody test1
Sample          ALT2       Bilirubin
 HBsAg   HBsAb    HBeAg     HBeAb      HBcAb
1      +       –        +         –          +           39.8              11.7
2      +       –        +         –          +           18.7                7.5
3      –       +        –         –          –           71.7              19
4      –       +        –         –          –           33.8                4.6
5      –       –        –         –          –           18.7                6.2
1HBsAg: hepatitis B surface antigen; HBsAb: antibody to HBsAg; HBeAg:
hepatitis B e antigen; anti-HBe: antibody to HBeAg; anti-HBc: antibody to
hepatitis B core antigen (HBcAg). 2ALT: alanine aminotransferase. +Represents
positive; – represents negative.
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and semen. The PCR reactions were set in 20 µL volume
containing 100 mmol/L Tris-HCl (pH 8.0), 2.5 mmol/L
MgCl2, 1 unit of  Taq DNA polymerase (Premega, Wisconsin,
USA), 200 µmol/L each of the deoxynucleotide, triphosphates
(dNTP), 1 µmol/L each of primers, and 1 µL viral DNA
as template in each reaction. Thermal cycling included an
initiation step at 94  for 3 min, followed by 40 cycles at
94  for 30 s, at 60  for 30 s, and at 72  for 60 s.
Products were visualized on agarose gels after electrophoresis.
Quantification of HBV viral DNA in serum and semen by
real-time PCR
Each 20-µL reaction contained 2 µL of sample extracts
(template), 250 nmol/L of the probe, 900 nmol/L of each
PCR primer, and 10 µL Master Mix (Roche, New Jersey,
USA). PCR was performed using the ABI 7900HT sequence
detection system. PCR cycling program consisted of an
initial background eliminating step at 50  for 5 min and a
HotStart activation step at 95  for 10 min, followed by
40 amplification cycles at 95  for 15 s, and at 61  for
40 s. The PCR products were further confirmed by
electrophoresis loaded in 2% agarose gels. The experiments
were repeated twice.
RESULTS
Detection of HBV DNA in sera and semen by PCR
To detect hepatitis B viral DNA in the semen, HBV DNA
was isloated from 200 µL of semen using QIAamp blood
mini kit. Viral DNA was also isolated from the sera to serve
as a control. Conventional PCR was carried out to amplify
a 480-bp of DNA fragment. A specific fragment was
amplified from viral DNA templates isolated from both
sera and semen of HBV carriers (Patients 1 and 2), indicating
that hepatitis B viruses existed in the semen of HBV carriers
(Figure 1). The bands amplified from serum DNA (lanes 2
and 4) were much stronger than those amplified from semen
DNA (lanes 3 and 5), indicating that the viral titers were
much lower in semen than in sera. No DNA fragment was
amplified from the samples (sera and semen) from the
patient with HBsAb only or without any HBV markers
(Patients 3-5, data not shown).
Figure 1  Detection of HBV DNA in sera and semen of HBV carriers by PCR.
Lane 1: 100 bp DNA ladder; lanes 2 and 3: sera and semen of patient 1; lanes
4 and 5: sera and semen of patient 2; lane 6: positive control (pHBV plasmid).
Quantification of HBV DNA in sera and semen by real-time
PCR
To test the performance of  our primers and probes in
real-time PCR, we used 10, 102, 103, 104, 105, 106, and
107 copies of HBV DNA[17]. Our results showed that
amplification performance was good in all reactions
(Figure 2A). A linear relationship was observed between
10 and 107 copies of HBV templates (Figure 2B). The viral
titers in the sera and semen of patients were further
quantified by real-time PCR. The consistent values of the
qPCR were obtained by three independent qPCR (Table 2).
We detected 7.56×107 copies of  HBV per mL in the sera,
but only 2.14×105 copies per mL in the semen of patient 1.
Similar results were obtained from patient 2. We observed
that the ratio of viral load in semen to sera was 0.3% in
patient 1 and 1.8% in patient 2, respectively. The viral DNA
isolations with different methods did not result in a
statistically-significant difference (Student’s t-test). As we
expected, no viral DNA was detected in the samples from
non-infected patients (patient 5) or from the patient with
positive HBsAb only (patients 3 and 4).
To validate whether our methods could apply to low-
volume semen samples, we isolated HBV DNA from 10, 50
and 200 µL of semen and quantified HBV DNA copies by
real-time PCR. Again, all experiments produced consistent
results (Table 3), indicating that our methods could indeed
be used to quantify HBV DNA with low-volume semen
samples.
Figure 2  Real-time PCR profile. The amplification profile when 10-107 copies
of HBV DNA were used (A) and standard curve (B).
DISCUSSION
In this study, we found that TaqMan technology-based
real-time PCR assay could be used to quantify HBV DNA
in semen. As this method is highly sensitive and reproducible,
and has a wide dynamic linear range, it can be used to
monitor HBV viral load in small samples of body fluids.
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The detection threshold of this assay is 10 copies of HBV
DNA per reaction.
Traditionally, HBV in sera is monitored by antigen/
antibody test, Dot blot, Southern blot, branched DNA
assay, or hybrid capture test[2,18,19]. The minimal template
requirement for these assays on blood is at least 7×105
copies of HBV DNA per millilter. The threshold of Roche
Cobas RT-PCR commercial kit is 400 copies and that of
New England DNA kit is around 100 copies. Due to
sensitivity limitations, these requirements often give rise to
problems in clinical settings. A large portion of HBV patients
with undetectable viral antigens or viral DNA often relapse
after the cessation of anti-HBV treatments[19], and for this
reason real-time PCR has been recently introduced to
monitor HBV viral load in sera[18,21]. In this study, we
introduced real-time PCR method to quantify HBV DNA
in semen of  HBV carriers. Possible PCR inhibitors in the
seminal extracts may cause false results. To exclude this
possibility, we measured viral load from a sample extracted
by different methods, as well as by the same method but
with a different amount of samples. Our assay produced
consistent reproducible results (Tables 2 and 3). These
results indicated that this method is highly accurate and
reproducible.
Theoretically, our quantification method may be used
to quantify HBV DNA with multiple genotypes or mutants.
Since HBV genome undergoes fast mutagenesis, the designed
PCR primers may not match to a special HBV template or
a mutated HBV template with reduced sensitivity. To make
our assay applicable to most HBV genotypes, we aligned
multiple HBV genome sequences containing most genotypes,
and then designed primers targeting the most conserved
core region. In addition, we defined the hot spot mutation
sites in the HBV genome and designed degenerated PCR
primers that could match the natural HBV templates or
accumulated HBV mutations during anti-HBV treatment.
The use of  TaqMan probe-based real-time PCR to
quantify HBV DNA in body fluids has a number of
advantages. Firstly, it is highly sensitive and accurate. As
shown in Figure 2, as few as 10 copies of HBV template
(corresponding to 500 copies of HBV DNA/mL semen)
were sufficient to produce a marked amplification profile
in the PCR reaction, and a wide linear range from 10 to 107
copies of HBV DNA was obtained. Real-time PCR can
therefore be used to monitor HBV DNA in small samples
of  body fluid. Secondly, it has a low background. We noticed
that there was no detectable HBV DNA either in the sera
of  non-HBV-carriers or in the semen of  patients 3-5. When
reaction and detection are carried out in the same reaction
tube, the chance of contamination is greatly reduced. Thirdly,
it could produce a very small number of false positive results.
Positive results can only be obtained when PCR primers
and molecular probes work in a small genomic element
simultaneously. The chance of three specific primers
targeting any other templates is very low. In our experiment,
HBV DNA was not detected in the samples from non-
HBV-infected patients. Fourthly, no PCR inhibitors were
found in the semen, because consistent results were obtained
from different DNA isolation methods. Finally, the method
is quick and easy, and has a high throughput. A large number
of samples can be simultaneously tested on a 96-well plate
within 2-3 h. This is a particularly important consideration
in clinical settings. There are about 200 million HBV
carriers in China, and doctors need to know the HBV status
of patients before medical treatments such as assisted
reproduction, surgery, transfusion, and transplantation.
These advantages make a popular way of quantifying HBV
DNA in body fluids in the near future.
In summary, quantitative real-time PCR is a simple,
sensitive, specific, and reproducible assay for the measurement
of HBV viral load in semen. The viral load in body fluids,
including semen and vaginal secretions, is an important
parameter for the estimation of risk factor for HBV
transmission through sexual contact.
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